Material Event (Form 8-K)

Item 8.01. Other Events.

As previously disclosed, on April 20, 2026, The Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Staff (the "Staff") issued a letter to ENDRA Life Sciences Inc. (the "Company") indicating that the Company's stockholders' equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 was below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1) (the "Minimum Stockholders' Equity Requirement"). On April 27, 2026, in accordance with the Staff's letter, the Company requested a hearing before the Nasdaq Hearing Panel, and a hearing was held on May 28, 2026.

On July 8, 2026, the Company received written notice (the "Notice") from Nasdaq indicating that the Company has regained compliance with the Minimum Stockholders' Equity Requirement.

Pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a Discretionary Panel Monitor for a period of one year from July 1, 2026. If, within the one-year monitoring period, the Staff finds the Company again out of compliance with any of Nasdaq's Listing Rules, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, pursuant to the Notice, the Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. Pursuant to the Notice, the Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company's securities may be at that time delisted from Nasdaq.